Sponsored by:
CONTINUOUS CHROMATOGRAPHY
PUSHING THE BOUNDARIES OF PEPTIDE AND OLIGONUCLEOTIDE PRODUCTION
During the manufacturing of an API, well-established purification is crucial for achieving high purity and yield, and at the same time is a major determinant for the cost efficiency and process productivity. Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) has shown to achieve substantially higher capacity and yield than single- column batch processes. This innovative purification process leads to time savings, economic advantages and a lower environmental footprint.
Ralf Eisenhuth
Process Manager Chromatography and Technology Transfer Oligonucleotides
Ralf Eisenhuth received his Ph. D. in Organic synthesis from the University of Karlsruhe with specialization in nucleoside and oligonucleotide synthesis. Ralf joined Bachem in 2008 as a Team leader in API manufacturing. Since then, he worked in various positions including Director of the department Large Scale Purification at Bachem in Bubendorf. In his current position, he is the Process Manager Chromatography and Technology Transfer. There, his main interests are new technologies and intensification of existing processes.
Daniel Samson
Vice President, Head Oligonucleotides
Daniel brings 15 years of industry experience to the team, with an emphasis on TIDES process R&D, manufacturing and CMC development. He leads Bachem’s oligonucleotide unit including innovation projects, R&D and manufacturing activities. Daniel holds a PhD in organic chemistry from the University of Konstanz, and an MBA from the International Institute for Management Development (IMD), Lausanne. In previous stages of his career he was a lab head for process optimization, technology transfer, Quality by Design, and scale-up of synthetic peptide manufacturing procedures. From 2012, Daniel was a Vice President API Manufacturing and had full responsibility for all large-scale solid phase peptide and oligonucleotide syntheses, downstream operations, and CMC activities within Bachem AG. On March 1, 2022, Daniel assumed a new position as Vice President, Head Oligonucleotides at Bachem.
